MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-166 in ALS at 26th International Symposium on ALS/MND in Orlando, FL

MediciNova, Inc. MNOV announced that principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System's Neuromuscular/ALS-MDA Center, today presented interim data from MediciNova's ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the 26th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) in Orlando, FL.  The interim analysis includes a total of 36 subjects, and 33 of those subjects completed 6 months of treatment on study drug (MN-166 or placebo in a 2:1 ratio). Major highlights from the presentation, "Adaptive Design Single Center Phosphodiesterase Type 4 (PDE4) Inhibitor – Ibudilast (MN-166) Phase 1b/2a Clinical Trial [NCT02238626] for Amyotrophic Lateral Sclerosis (ALS) Patients [1] Not Requiring Non-Invasive Ventilation (no-NIV) up to 5 years and [2] Requiring Non-Invasive Ventilation (NIV) up to 10 years from Disease Onset," include the following: The rate of decline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score, a measure of functional impairment, from Baseline to Month 6 for the MN-166 and placebo subjects combined is below See full press release